SARCLISA (isatuximab-irfc) is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including
Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab) in combination with carfilzomib and dexamethasone (Kd), for
Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
S
S
Patients with high‐risk CA treated with daratumumab, bortezomib, and dexamethasone exhibited prolonged PFS (HR: 0
Generic name: dexamethasone (oral) [ dex-a-METH-a-sone ] Brand names: Decadron, DexPak 6 DayTaperpak, Hemady
Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3
S
Food and Drug Administration recommendations on censoring rules, showed mPFS increased from 20
All patients should be premedicated with oral corticosteroids (see below for prostate cancer) such as dexamethasone 16 mg per day (e
It is freely soluble in water and is exceedingly hygroscopic
This prespecified subgroup analysis examined efficacy in patients with renal impairment (RI; estimated glomerular filtration rate <60 mL/min/1
1% of patients achieved undetectable levels of disease after 18 weeks of induction treatment with Sarclisa-RVd; Oncology at Sanofi
The study design has been reported previously (10,16); briefly, patients who had received 1–3 prior lines of therapy were randomized 3:2 to receive isatuximab-carfilzomib-dexamethasone (isatuximab arm) or carfilzomib-dexamethasone (control arm)
Severe reactions require immediate discontinuation of TAXOTERE and administration of appropriate therapy (5
Sarclisa ® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
83) with a median of 12
Isatuximab (isatuximab-irfc; Sarclisa®) is an IgG1 monoclonal antibody that binds to the glycoprotein CD38 expressed on the surface of haematopoietic and tumour cells
11 Department of Hematology, University of California at San Francisco, (Isa) plus carfilzomib and dexamethasone (Kd; Isa-Kd) versus Kd in patients with relapsed MM (updated median PFS: 35
A study of daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by ciltacabtagene autoleucel versus daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by autologous stem cell transplant (ASCT) in participants with newly diagnosed multiple myeloma
It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced New data from fast-growing innovative Oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting